Clinical TrialApr 29, 2026, 07:02 AM
OKYO to Present Positive Urcosimod NCP Data at ARVO & Eyecelerator
AI Summary
OKYO Pharma announced its CEO and CSO will present at upcoming scientific conferences, Eyecelerator and ARVO. The CSO will present positive data from the First-in-Human study of Urcosimod for Neuropathic Corneal Pain (NCP) at ARVO, showing clinically meaningful pain reduction and quality-of-life improvement. Urcosimod, which has FDA Fast Track designation, recently showed positive data in an 18-patient Phase 2 trial for NCP, and the company plans to initiate a 150-patient Phase 2b/3 study in the first half of this year.
Key Highlights
- OKYO CEO Robert J. Dempsey to present at Eyecelerator on May 1, 2026.
- OKYO CSO Raj Patil to present at ARVO Annual Meeting on May 5, 2026.
- ARVO presentation to detail positive data from Urcosimod's First-in-Human study for Neuropathic Corneal Pain (NCP).
- Urcosimod showed clinically meaningful pain reduction and quality-of-life improvement in NCP patients.
- Urcosimod is the first investigational therapy with an IND for NCP and has FDA Fast Track designation.
- Company recently announced positive data from an 18-patient Phase 2 trial for NCP.
- OKYO plans to initiate a 150-patient Phase 2b/3 multiple-dose study for NCP in H1 2026.